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Background: Microalbuminuria is an early manifestation of kidney damage and independently predicts cardiovascular
disease (CVD). Left ventricular hypertrophy (LVH) is also an early marker of cardiac manifestation of target organ
damage among hypertensive patients. The prognostic significance of microalbuminuria and its correlation with left
ventricular hypertrophy has not been extensively studied in African adult hypertensive populations. This study aimed at
determining the prevalence of microalbuminuria, LVH in patients with microalbuminuria and the correlation between
microalbuminuria and LVH among newly diagnosed black adult hypertensive patients attending a large outpatient
hypertension clinic or admitted on the cardiology ward at Mulago national referral and teaching hospital and Uganda
Heart Institute in Kampala, Uganda.
Methods: In this cross-sectional study, 256 newly diagnosed eligible black adult hypertensive patients attending the
outpatient hypertension clinic or admitted on the cardiology ward at Mulago national referral and teaching hospital
and the Uganda Heart Institute, Kampala Uganda were consecutively recruited over a period of 5 months. Data on
socio-demographics, clinical and laboratory findings of the study participants was collected using a pre tested
questionnaire. Two spot urine samples were collected to assess for microalbuminuria. Echocardiography (ECHO)
was done to assess for the left ventricular mass index using the formula of Teicholz as evidence for early hypertensive
heart disease.
Results: The mean age/standard deviation of the study participants was 54.3 ± 6.2 years with a female predominance
(162, 63.3 %). The prevalence of microalbuminuria among newly diagnosed hypertensive patients was 39.5 %. The
prevalence of LVH among patients with microalbuminuria was found to be 17 %. There was a positive correlation
between microalbuminuria and left ventricular hypertrophy among the newly diagnosed adult hypertensive patients
at Mulago Hospital (r = 0.185, p = 0.003).
Conclusions: This study demonstrates that microalbuminuria is highly prevalent among newly diagnosed black
hypertensive patients and in the presence of LVH. There is also a positive correlation between microalbuminuria and
LVH among newly diagnosed hypertensive patients. Since it is a less costly and readily available test, it can be used to
predict presence of LVH especially in resource limited settings where ECHO services are not readily available.
Keywords: Microalbuminuria, left ventricular hypertrophy, Left ventricular mass index, Newly diagnosed hypertensive
patients, Cross sectional study, Africa, Uganda* Correspondence: jgnabbaale@gmail.com
1Uganda Heart Institute, Mulago Hospital, P.O. Box 7051, Kampala, Uganda
Full list of author information is available at the end of the article
© 2015 Nabbaale et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Nabbaale et al. BMC Research Notes  (2015) 8:198 Page 2 of 7Background
Recent evidence demonstrates that cardiovascular diseases
(CVD) are the commonest cause of deaths globally.
Low- and middle-income countries are disproportion-
ally affected, with over 80 % of CVD deaths occurring
in these countries [1, 2]. Hypertension (HT) is a grow-
ing public health problem and it is now being widely
reported in many rural and urban parts of Sub Saharan
Africa (SSA) as one of the commonest cause of morbidity
and mortality [3].
The reasons for this growing burden are multiple,
ranging from socio-economic changes and genetic in-
fluence. At a genetic level, there is growing evidence
showing an association between elevated diastolic BP
and CaMK4 affecting endothelial functions like controlling
vascular resistance hence increasing the risk of HT [4].
Recently, a burgeoning burden of HT has been de-
scribed both in rural and urban areas of Uganda. One
earlier community based study conducted in the former
Teso district in 1941 reported a very low frequency of
HT of 2.9 % among adults aged 21-50 years [5]. Another
similar population based study was conducted in the
early 1960’s in Kasangati, a rural community outside of
Kampala city revealed prevalence of 13.7 % [6]. Recent
similar studies have documented age standardized HT
prevalence to range between 14.6 % to 30.5 % [7–10]. In
one rural study, a pre HT, an antecedent to clinically de-
tected HT was reported to occur in 33.9 % of the study
participants [9].
Microalbuminuria is an early indicator of renal damage
and has been demonstrated as one of the principal pre-
dictive factors of cardiovascular (CV) complications, all
cause and cardiovascular mortality independent of the
traditional risk factors like dyslipidemia, hypertension
[11, 12]. Left ventricular hypertrophy (LVH) determined
either by standard 12-lead electrocardiography (ECG) or
echocardiography is also a marker of subclinical organ
damage related to hypertension and an independent pre-
dictor of cardiovascular morbidity/mortality [13].
Regression of microalbuminuria and LVH with standard
anti hypertensive therapy (mainly with angiotensin con-
verting enzyme inhibitors) is associated with a significant
reduction in the associated CV morbidity and mortality
[14]. Beta blockers especially the cardio selective ones also
possess a role in LVH regression, albeit a minor role [15].
There is paucity of studies on the burden of microalbu-
minuria and its correlation with LVH among black African
newly diagnosed adult HT patients in Uganda. This study
therefore aimed at examining the burden of microalbumi-
nuria and its correlation with LVH in newly diagnosed
adult HT patients attending the outpatient hypertension
clinic or admitted on the cardiology ward at Mulago na-
tional referral and teaching hospital and the Uganda Heart
Institute, Kampala Uganda.Methods
Study design and setting
This cross sectional study was carried out in the out-
patient hypertension clinic, the cardiology ward of Mulago
national referral and teaching hospital, Kampala Uganda
and the Uganda Heart Institute, Kampala Uganda. Mulago
hospital serves as the national referral hospital and univer-
sity teaching hospital for the Makerere University College
of Health Sciences. It has a 1500 bed capacity.
Study population and sampling technique
The study population comprised of 256 newly diagnosed
eligible adult hypertensive patients attending the outpatient
hypertension clinic or admitted on the cardiology ward at
Mulago national referral and teaching hospital and the
Uganda Heart Institute in Kampala, Uganda. The inclusion
criteria into the study were: newly diagnosed adult hyper-
tensive patients (aged ≥18 years of age) and those who gave
written informed consent to participate in the study.
Patients with documented chronic kidney disease,
catheterization, fever (temperature above 37.5 °C), con-
gestive cardiac failure, female patients who were menstru-
ating, active urinary tract infection, patients with diabetes
mellitus, those taking ACEIs, obese patients and those
who had been under vigorous exercise in the past 24 h
were excluded from the study (Fig. 1). Vigorous exercise
was defined as that which could cause sweating, heavy
breathing or fast heart beat like brisk walking in our Afri-
can context.
They were consecutively recruited over a period of
5 months (June to October 2012) until the calculated
sample size was attained.
Sample size calculation
Using prevalence of 21.3 % of microalbuminuria among
newly diagnosed hypertensive patients reported by Rayner
B et al in South Africa in 2006 [16], with an 80 % power
and a two sided α < 0.05, a sample size of 256 was esti-
mated using the Kish Leslie (1965) formula.
Data collection
A pre tested questionnaire was used to collect the
socio-demographic and clinical data of the study partic-
ipants. Blood pressure was measured using standard
procedures using a standard Manual Dekamet Accoson
MK3® mercury sphygmomanometer machine. Using stand-
ard methods, anthropometric measurements of weight in
kilograms (kg) and the height in meters (m) were also per-
formed and body mass index (BMI) calculated using the
formula, BMI =weight in kg/height in m2.
Assessment of microalbuminuria
The study participants were first instructed about the
process of collecting a midstream urine sample. They
History, exam and questionnaire 
filled. 
Enrolled 350 newly diagnosed 
hypertensive patients at MOPD, 
UHI, 3BEM, 4C Cardiology 
12    Active UTI 
5      Febrile T>37.5°C 
20    Documented kidney   
        disease 
9      CCF 
21    DM  
7      Menstruating females 
20    Obese 
Urinalysis for microscopy and 
microalbuminuria and then cardiac 
ECHO performed for LVH. 
256 participants fulfilled the    
         inclusion criteria.  
Fig. 1 Patient flow chart on recruitment
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to provide two samples of about 10 mls of mid-stream
urine. One sample was collected in a sterile bottle for
urinalysis including microscopy of the urine sediment.
The second one was collected in a urine container with
a preservative called 0.2 % sodium-azide for measuring
of urinary albumin. The urine samples were sent to the
Uganda Heart Institute laboratory for analysis which was
done by the Immuno-turbidimmetric Method (RAN-
DOX). Microalbuminuria was defined as a random urine
albumin level between 30 and 299 mg/dl.
Echocardiography (ECHO) performance for assessing LVH
A trans thoracic ECHO was done by an experienced car-
diologist with experience in echocardiography and clin-
ical cardiology using a GE Vivid 7 echocardiography
machine LV mass index was calculated using Teicholz
formula where increased LV Mass index was values >
125 g/m2.
Data analysis
Data was coded and double entered in EpiData, cleaned
and exported to STATA10 for analysis. Descriptive ana-
lysis of the study population was conducted. Pearson
chi-square X2 and odds ratio analysis was applied todetermine strength of association for categorical risk
factors. A p-value of less than 0.05 was considered
significant.
Association between microalbuminuria, LVH and the
study variables were compared to test the strength of
the association between them and the variables that in-
cluded age, sex, education level, marital status and occu-
pation. The prevalence of microalbuminuria was
determined using proportions. The correlation between
microalbuminuria and LVH was determined using
Spearman’s rank correlation analysis technique.
Ethical consideration
This study was approved by the department of medicine,
College of Health Sciences Makerere University and the
research and ethics committee of the School of Medi-
cine, Makerere University Kampala Uganda. All the
study participants provided written informed consent to
participate in this study.
Results
Socio demographic characteristics of study participants
The mean age/standard deviation of the study partici-
pants was 54.3 ± 6.2 years with a female predominance
(162, 63.3 %). The age range of the study participants
Table 2 Age-adjusted prevalence of microalbuminuria in age
groups
Age Frequency (N) Non–age adjusted (%) Age-adjusted
prevalence (%)
18–34 34 12 1.6
35–54 110 42 18
55–74 85 32 10.6
75–94 27 14 1.48
Total 256 100 31.7 %
Nabbaale et al. BMC Research Notes  (2015) 8:198 Page 4 of 7was from 17 to 94 years with majority aged between 35–54
years (43.0 %) and 55–74 years (33.2 %). Table 1 and Fig. 1
summarize the socio demographic characteristics and the
flow chart of the study participants respectively.
Prevalence of microalbuminuria and LVH
The overall prevalence of microalbuminuria and LVH
among the study participants was 39.5 % and 14.1 % re-
spectively. The age adjusted prevalence of microalbumi-
nuria (31.7 %) was lower compared to the unadjusted
prevalence as shown in Table 2.
According to the different categories of HT, 72 %, 8 %
and 2 % of the study participants with controlled HT,
stage 1 and stage 2 HT had microalbuminuria respect-
ively. LVH was highly prevalent among the patients with
stage 2 hypertension (85 %) and controlled HT (12 %).
Only 12 % of the participants who had stage 1 hyperten-
sion had LVH.
Prevalence of LVH among study participants with
microalbuminuria and according to age categories
The prevalence of LVH among the study participants
with microalbuminuria was 17 %, higher than the overall
study prevalence of LVH of 14.1 % (shown in Table 3).
LVH was more prevalent in the older age groups of 55–74
(15, 41.7 %) and 75–94 years (6, 16.7 %) compared to the
younger age groups (Table 4).Table 1 Socio-demographic characteristics of study participants





18 – 34 34 13.3
35 – 54 110 43
55 – 74 85 33.2
75 – 94 27 10.5
Level of education
No Formal education 42 16.4
Primary education 88 34.4
Secondary education 66 25.8







Widowed 39 15.2Prevalence microalbuminuria and LVH according to BMI
Microalbuminuria was detected in 72.3 %, 18.2 % and
9.1 % of the study participants with a normal BMI,
under weight and overweight respectively. LVH occurred
in 66.7 %, 19.4 % and 13.9 % of study participants with
normal BMI, underweight and overweight respectively.
Prevalence of microalbuminuria and LVH across stages of
HT (Major revision 1)
Seventy two percent (72 %) of the study participants
with controlled hypertension had microalbuminuria,
while 8 % of those who had stage 1 hypertension had
microalbuminuria. Only 2 % of tho study participants
who had stage 2 hypertension had microalbuminuria.
Sixty eight (68 %) of the study participants who had con-
trolled hypertension had LVH while 12 % of the partici-
pants who had stage 1 hypertension had LVH and 85 %
of the participants in stage 2 hypertension had LVH.
Prevalence of hypertensive heart failure clinically and by
echocardiography
52.3 % of the study participants had diastolic heart failure
and 18.7 % of the study participants had systolic heart
failure on echocardiography. However, 46.7 % of the
same study participants had Class 1 NYHA symptoms,
24.1 % were in class 11, 9.2 % were in class 111 and
only 2 % of the study participants were in class 1 V.
Correlation between microalbuminuria and LVH among
study participants
As shown in Table 5, there was a positive correlation be-
tween microalbuminuria and LVH (r = 0.185, p = 0.003).
This close association is further illustrated by the bivariate




Microalbuminuria Present 17 (17.0 %) 83 (83.0 %) 100 (39.5 %)
Absent 19 (12.2 %) 137 (87.8 %) 156 (60.5 %)
Total 36 (14.1 %) 220 (85.9 %) 256 (100 %)
Table 4 Prevalence of LVH among different age categories
LVH 15–34 35–54 55–74 75–94 Total
Present Frequency 2 (5.6 %) 13 (36.1 %) 15 (41.7 %) 6 (16.7 %) 36 (14.1 %)
Absent Frequency 32 (14.5 % 97 (44.1 %) 70 (31.8 %) 21 (9.6 %) 220 (85.9 %)
Total 34 110 85 27 256
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To our knowledge, this is the first study to assess the bur-
den of microalbuminuria and its correlation with LVH
among newly diagnosed adult HT patients in Uganda, a
country with a growing burden of CVD. It unequivocally
illustrates a high overall prevalence of microalbuminuria
and LVH of 39.5 % and 14.1 % respectively, both features
of target organ damage among the study participants in
Uganda. These proportions represent a significant group
of newly diagnosed adult hypertensive individuals who are
at an increased risk of CV morbidity and mortality. The
study also noted a positive correlation between LVH and
microalbuminuria.
The reported prevalence of microalbuminuria in our
study is comparable to what has been reported in one
large international multi-center study [17] and in other
African hypertensive populations [16, 18, 19]. In the inter-
national, observational, practice-based study i-SEARCH
(Survey for Evaluating Microalbuminuria Routinely by
Cardiologists in patients with Hypertension) that was
designed to assess the frequency with which microalbumi-
nuria occurred in a large outpatient population of 21,050
patients who were currently treated or newly diagnosed
with hypertension and were under professional care in 26
countries, a high overall prevalence of microalbuminuria
of 58.4 % noted [17].
Microalbuminuria was significantly related to the pres-
ence of specific predictors, including male gender, abnor-
mally high waist circumference, increased blood pressure
levels (systolic ≥120 mmHg, diastolic ≥100 mmHg), cre-
atinine clearance ≥50 ml/min, or clinical conditions such
as diabetes mellitus, congestive heart failure, history of
cerebral pathology, and peripheral arterial disease.
Among African hypertensive populations, in a study














N 256 256described above (i-SEARCH study), the prevalence of
microalbuminuria among the 476 patients recruited
from 40 cardiology centers was 67.8 % [18]. This high
prevalence in the Moroccan study compared to the one
documented in the global study (58.4 %) could probably
be explained by the high proportion of patients with
suboptimal blood pressure control (81.4 %) and presence
of multiple co-existing CV risk factors like diabetes
mellitus, dyslipidemia and obesity which influence
microalbuminuria (≥65 % of the patients had ≥3 CV
risk factors).
In another similar study done in Nigeria, the preva-
lence of microalbuminuria in 96 newly diagnosed non
diabetic hypertensive patients was 32.3 % compared to
6.3 % in age and sex matched controls [19]). In a multi
racial South African study among 1901 ambulatory
hypertensive patients, the overall prevalence of microal-
buminuria was 21.3 % [16]). The independent predictors
of microalbuminuria were severe hypertension (OR 2.9,
p < 0.0001), type 2 diabetes (OR 2.5, p < 0.002), and
Asian ethnic group (OR 2.0, p = 0.02).
LVH in our study was documented in 14.1 % of the
study participants, a finding comparable to that in the
South African study (18.9 %) [16]. In our study, LVH was
also more frequent in patients with microalbuminuria
compared to those without (17 % vs. 12.2 %). A higher fre-
quency of LVH in patients with microalbuminuria has also
been described in other similar studies [19–21].
The correlation between microalbuminuria and LVH
in our study was found to be positive with a correlation
coefficient of 0.185 and p value of 0.003. Similarly,
microalbuminuria has been shown to positively correlate
with LVH in other large studies [22, 23] and other car-
diac abnormalities like left ventricular dysfunction and
ischemic heart disease [24].
Microalbuminuria as a marker of early renal damage
reflects widespread vascular damage (microangiopathy),
a pro inflammatory state (with increased levels of IL-6,
TNF-α, CRP and fibrinogen) and ensuing endothelial
dysfunction. In addition to hypertension, microalbumi-
nuria can also result from other unfavorable metabolic
profile like hyperinsulinaemia and dyslipidemia [11, 12].
This hence augments development and progression of
atherosclerotic disease.
With advancing stages of HT, it has been illustrated
that both microalbuminuria and LV mass increase with
worsening BP levels. LVH as a marker of target organ
Fig. 2 Scatter plot showing the correlation between microalbuminuria and LVH
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independent association with a pro inflammatory state,
and in particular elevated fibrinogen levels, which is as-
sociated with development of atherosclerosis [25].
Other than persistently increased volume or pressure
overload on the left ventricle as occurs in HT, LVH can
develop in aortic stenosis, hypertrophic cardiomyopathy
and physiological LVH as seen in athletes.
Conclusions
This study demonstrates a high prevalence of microalbu-
minuria and LVH, predictors of CV morbidity and mortal-
ity in this patient subgroup in Uganda and a corresponding
positive correlation between both conditions.
Screening for urine albumin excretion should be ex-
tensively adopted in clinical care as a relatively simple,
readily available and cheap process to facilitate early
vascular disease detection as a strategy of averting HT
related complications like LVH and optimal management
in Uganda and SSA.
Study limitations
Microalbuminuria was assessed on a single occasion
using a spot urine sample although guidelines recom-
mend triple testing (2 out of 3 tests need to be posi-
tive). However, it has been suggested that diagnosis ofmicroalbuminuria can be more simply achieved by
using an efficient and accurate method of taking a spot
urine sample or an early morning urine specimen to
minimize changes that occur during the day, this
method does not require any special preparation prior
to collecting the urine sample. However, 24-h and over-
night urine collections are time consuming and often
inaccurate particularly because incomplete collections
are frequent. Vigorous exercise in 24 h preceding the
albuminuria test could have increased the prevalence in
our study patients however there was an attempt to
assess this cause, albeit subjectively.
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